Pathogenesis and Antifungal Drug Resistance of the Human Fungal Pathogen Candida glabrata
Open accessThe DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Abstract
Candida glabrata is a major opportunistic human fungal pathogen causing superficial as well as systemic infections in immunocompromised individuals and several other patient cohorts. C. glabrata represents the second most prevalent cause of candidemia and a better understanding of its virulence and drug resistance mechanisms is thus of high medical relevance. In contrast to the diploid dimorphic pathogen C. albicans, whose ability to undergo filamentation is considered a major virulence trait, C. glabrata has a haploid genome and lacks the ability to switch to filamentous growth. A major impediment for the clinical therapy of C. glabrata infections is its high intrinsic resistance to several antifungal drugs, especially azoles. Further, the development of antifungal resistance, particularly during prolonged and prophylactic therapies is diminishing efficacies of therapeutic interventions. In addition, C. glabrata harbors a large repertoire of adhesins involved in the adherence to host epithelia. Interestingly, genome plasticity, phenotypic switching or the remarkable ability to persist and survive inside host immune cells further contribute to the pathogenicity of C. glabrata. In this comprehensive review, we want to emphasize and discuss the mechanisms underlying virulence and drug resistance of C. glabrata, and discuss its ability to escape from the host immune surveillance or persist inside host cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174 · cited 2×
“reaching a mortality rate of up to ~35–40% for systemic or disseminated infections [1,2].”
BackgroundTargeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“consecutive activation of a number of distinct mechanisms operating in all living cells from bacteria to cancer cells [103-106].”
BackgroundThe Transcriptional Landscape of the Yeast Genome Defined by RNA Sequencing
Nagalakshmi, U., Wang, Z., Waern, K., Shou, C., Raha, D., Gerstein, M., & Snyder, M. (2008) · Science · doi:10.1126/science.1158441 · Cited by 2,479
The Genetic Landscape of a Cell
Costanzo, M., Baryshnikova, A., Bellay, J., Kim, Y., Spear, E. D., Sevier, C. S., Ding, H., Koh, J. L. Y., Toufighi, K., Mostafavi, S., et al. (2010) · Science · doi:10.1126/science.1180823 · Cited by 2,162 · cited 1×
“However, the remarkable and nearly endless combinatorial complexity of genetic interactions [121] will make it difficult to come up with meaningful cause-consequence conclusions based on small genomic or genetic differences identified by comparing S.”
BackgroundAntifungal agents: mechanisms of action
Odds, F. C., Brown, A. J. P., & Gow, N. A. R. (2003) · Trends in Microbiology · doi:10.1016/s0966-842x(03)00117-3 · Cited by 1,202 · cited 2×
“glabrata displays inherently high resistance to several antifungal drugs, limiting the efficacy of some antifungal drugs used in clinical therapy [7,79-81].”
BackgroundSanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815
Self-citationWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587
Pathogenic roles for fungal melanins
Jacobson, E. S. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.4.708 · Cited by 574 · cited 1×
“Such pigments have diverse biological functions, including antioxidative effects [58,59], which counteract reactive oxygen species (ROS) produced by the host immune system to kill and eliminate invading microbial pathogens [60].”
BackgroundResistance to echinocandin-class antifungal drugs.
Perlin, D. S. (2007) · Drug Resistance Updates · doi:10.1016/j.drup.2007.04.002 · Cited by 512
Hydrolytic enzymes as virulence factors of Candida albicans
Schaller, M., Borelli, C., Korting, H. C., & Hube, B. (2005) · Mycoses · doi:10.1111/j.1439-0507.2005.01165.x · Cited by 506 · cited 1×
“albicans [5-10].”
Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martı́nez, M., Calabrese, D., Sanglard, D., & Patterson, T. F. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2676-2684.2001 · Cited by 470 · cited 3×
“For C. albicans, one azole resistance mechanism is the overexpression or mutation of the azole target Erg11 [83,84].”
BackgroundInfluentialA Phenotypic Profile of the Candida albicans Regulatory Network
Homann, O. R., Dea, J., Noble, S. M., & Johnson, A. D. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000783 · Cited by 444 · cited 1×
“albicans or Cryptococcus neoformans [117,118].”
Systematic Genetic Analysis of Virulence in the Human Fungal Pathogen Cryptococcus neoformans
Liu, O. W., Chun, C. D., Chow, E. D., Chen, C., Madhani, H. D., & Noble, S. M. (2008) · Cell · doi:10.1016/j.cell.2008.07.046 · Cited by 443
Phagosome Extrusion and Host-Cell Survival after Cryptococcus neoformans Phagocytosis by Macrophages
Alvarez, M., & Casadevall, A. (2006) · Current Biology · doi:10.1016/j.cub.2006.09.061 · Cited by 414
Morgenstern, D. E., Gifford, M. A. C., Li, L. L., Doerschuk, C. M., & Dinauer, M. C. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.2.207 · Cited by 370 · cited 2×
“In addition, pathogen adhesion triggers extracellular host-derived ROS to kill pathogens [60].”
BackgroundA nuclear receptor-like pathway regulating multidrug resistance in fungi
Thakur, J. K., Arthanari, H., Yang, F., Pan, S.-J., Fan, X., Breger, J., Frueh, D. P., Gulshan, K., Li, D. K., Mylonakis, E., et al. (2008) · Nature · doi:10.1038/nature06836 · Cited by 343
Sanglard, D., Ischer, F., Calabrese, D., Majcherczyk, P. A., & Bille, J. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.11.2753 · Cited by 337
Garcia-Effron, G., Lee, S., Park, S., Cleary, J. D., & Perlin, D. S. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00443-09 · Cited by 323
Sanguinetti, M., Posteraro, B., Fiori, B., Ranno, S., Torelli, R., & Fadda, G. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.668-679.2005 · Cited by 319
Fungal ß(1,3)-D-glucan synthesis
Douglas, C. M. (2001) · Medical Mycology · doi:10.1080/mmy.39.1.55.66 · Cited by 312
Expulsion of Live Pathogenic Yeast by Macrophages
Ma, H., Croudace, J. E., Lammas, D. A., & May, R. C. (2006) · Current Biology · doi:10.1016/j.cub.2006.09.032 · Cited by 310
Ferrari, S., Ischer, F., Calabrese, D., Posteraro, B., Sanguinetti, M., Fadda, G., Rohde, B., Bauser, C., Bader, O., & Sanglard, D. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000268 · Cited by 295 · cited 3×
“In addition, strains harboring constitutively active PDR1 alleles also show increased virulence in mice, even in the absence of azole treatment [24].”
BackgroundStress, drugs, and evolution: the role of cellular signaling in fungal drug resistance.
Cowen, L. E., & Steinbach, W. J. (2008) · Eukaryotic Cell · doi:10.1128/ec.00041-08 · Cited by 285 · cited 2×
“glabrata displays inherently high resistance to several antifungal drugs, limiting the efficacy of some antifungal drugs used in clinical therapy [7,79-81].”
BackgroundVermitsky, J.-P., & Edlind, T. D. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3773-3781.2004 · Cited by 285 · cited 1×
“glabrata azole-resistant clinical isolates, neither overexpression nor ERG11 mutations seem to mediate resistance [85-87].”
BackgroundKaur, R., Ma, B., & Cormack, B. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611195104 · Cited by 284 · cited 6×
“Strains lacking the yapsins YPS1 and YPS7 or those lacking all eleven YPS genes, show attenuated virulence, implicating the YPS gene cluster in infectious processes [16].”
BackgroundMethodInfluentialA yeast by any other name: Candida glabrata and its interaction with the host
Kaur, R., Domergue, R., Zupancic, M. L., & Cormack, B. P. (2005) · Current Opinion in Microbiology · doi:10.1016/j.mib.2005.06.012 · Cited by 271
Albrecht, A., Felk, A., Pichova, I., Naglik, J. R., Schaller, M., de Groot, P., MacCallum, D., Odds, F. C., Schäfer, W., Klis, F., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509297200 · Cited by 270
Sanglard, D., Ischer, F., & Bille, J. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.4.1174-1183.2001 · Cited by 247
Catalases of Aspergillus fumigatus
Paris, S., Wysong, D., Debeaupuis, J.-P., Shibuya, K., Philippe, B., Diamond, R. D., & Latgé, J.-P. (2003) · Infection and Immunity · doi:10.1128/iai.71.6.3551-3562.2003 · Cited by 241
de Groot, P. W. J., Kraneveld, E. A., Yin, Q. Y., Dekker, H. L., Groß, U., Crielaard, W., de Koster, C. G., Bader, O., Klis, F. M., & Weig, M. (2008) · Eukaryotic Cell · doi:10.1128/ec.00284-08 · Cited by 232 · cited 1×
“The presence of adhesin-like proteins (Awp1-4) in the cell surface strongly depends on the strain background and the growth phase [33,37].”
BackgroundCryptococcus neoformans Resides in an Acidic Phagolysosome of Human Macrophages
Levitz, S. M., Nong, S.-H., Seetoo, K. F., Harrison, T. S., Speizer, R. A., & Simons, E. R. (1999) · Infection and Immunity · doi:10.1128/iai.67.2.885-890.1999 · Cited by 231 · cited 1×
“Moreover, phagolysosome maturation brings a hostile environment for pathogens, including hydrolytic enzymes as well as a lower pH due to acidification [73,74].”
BackgroundMechanism of Increased Fluconazole Resistance in Candida glabrata during Prophylaxis
Bennett, J. E., Izumikawa, K., & Marr, K. A. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.5.1773-1777.2004 · Cited by 217 · cited 2×
“glabrata azole resistance: Cdr1, Cdr2 (Pdh1) and Snq2 [25,92,93].”
Upregulation of ERG Genes in Candida Species by Azoles and Other Sterol Biosynthesis Inhibitors
Henry, K. W., Nickels, J. T., & Edlind, T. D. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2693-2700.2000 · Cited by 216 · cited 1×
“glabrata azole-resistant clinical isolates, neither overexpression nor ERG11 mutations seem to mediate resistance [85-87].”
BackgroundDeep sequencing of the zebrafish transcriptome response to mycobacterium infection
Hegedűs, Z., Zakrzewska, A., Ágoston, V. C., Ordas, A., Rácz, P., Mink, M., Spaink, H. P., & Meijer, A. H. (2009) · Molecular Immunology · doi:10.1016/j.molimm.2009.07.002 · Cited by 216
Lopez-Ribot, J. L., McAtee, R. K., Lee, L. N., Kirkpatrick, W. R., White, T. C., Sanglard, D., & Patterson, T. F. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.11.2932 · Cited by 210
Candida albicans drug resistance—Another way to cope with stress
Cannon, R. D., Lamping, E., Holmes, A. R., Niimi, K., Tanabe, K., Niimi, M., & Monk, B. C. (2007) · Microbiology · doi:10.1099/mic.0.2007/010405-0 · Cited by 208
Formation of new chromosomes as a virulence mechanism in yeast Candida glabrata
Poláková, S., Blume, C., Zárate, J. Á., Mentel, M., Jørck-Ramberg, D., Stenderup, J., & Piškur, J. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809793106 · Cited by 206 · cited 3×
“Interestingly, chromosomal rearrangements often occur at the same loci, as several isolates showed duplicated segments carrying genes associated with drug resistance (CDR1, CDR2) or survival in macrophages (YPS gene cluster [16]) [63].”
BackgroundHallstrom, T. C., & Moye-Rowley, W. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m007338200 · Cited by 194 · cited 1×
“glabrata [108-110].”
Cuéllar-Cruz, M., Briones-Martin-del-Campo, M., Cañas-Villamar, I., Montalvo-Arredondo, J., Riego-Ruiz, L., Castaño, I., & De Las Peñas, A. (2008) · Eukaryotic Cell · doi:10.1128/ec.00011-08 · Cited by 190
Telomere length control and transcriptional regulation of subtelomeric adhesins in Candida glabrata
Castaño, I., Pan, S., Zupancic, M., Hennequin, C., Dujon, B., & Cormack, B. P. (2005) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04465.x · Cited by 188
Modulation of histone H3 lysine 56 acetylation as an antifungal therapeutic strategy
Wurtele, H., Tsao, S., Lépine, G., Mullick, A., Tremblay, J., Drogaris, P., Lee, E.-H., Thibault, P., Verreault, A., & Raymond, M. (2010) · Nature Medicine · doi:10.1038/nm.2175 · Cited by 157
Infection-related gene expression in Candida albicans
Brown, A. J. P., Odds, F. C., & Gow, N. A. R. (2007) · Current Opinion in Microbiology · doi:10.1016/j.mib.2007.04.001 · Cited by 148
Smith, W. L., & Edlind, T. D. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3532-3539.2002 · Cited by 147 · cited 1×
“Notably, induction of the ABC transporters CDR1 and CDR2 upon fluconazole treatment is significantly reduced in the presence of the histone deacetylase inhibitor trichostatin A [112].”
BackgroundGlycan microarray analysis of Candida glabrata adhesin ligand specificity
Zupancic, M. L., Frieman, M., Smith, D., Alvarez, R. A., Cummings, R. D., & Cormack, B. P. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06184.x · Cited by 143 · cited 1×
“The major epithelial adhesins, Epa1, Epa6 and Epa7, display different binding specificities concerning decoration of host cell ligands containing a terminal galactose residue [36].”
BackgroundAutophagy supports Candida glabrata survival during phagocytosis
Roetzer, A., Gratz, N., Kovarik, P., & Schüller, C. (2010) · Cellular Microbiology · doi:10.1111/j.1462-5822.2009.01391.x · Cited by 142 · cited 2×
“CTA1 Increased susceptibility to oxidative stress [22,23] ATG11, ATG17 Reduced survival upon phagocytosis [22] PDR1 Increased azole susceptibility; GOF mutations: increased virulence and organ colonization, azole resistance [24]”
BackgroundTorelli, R., Posteraro, B., Ferrari, S., La Sorda, M., Fadda, G., Sanglard, D., & Sanguinetti, M. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06143.x · Cited by 141
Iraqui, I., Garcia‐Sanchez, S., Aubert, S., Dromer, F., Ghigo, J., D’Enfert, C., & Janbon, G. (2005) · Molecular Microbiology · doi:10.1111/j.1365-2958.2004.04475.x · Cited by 126 · cited 1×
“Gene Deletion phenotype References EPA gene family Reduced adherence, organ colonization and biofilm formation [11,12,13,14,15]”
BackgroundRoetzer, A., Gregori, C., Jennings, A. M., Quintin, J., Ferrandon, D., Butler, G., Kuchler, K., Ammerer, G., & Schüller, C. (2008) · Molecular Microbiology · doi:10.1111/j.1365-2958.2008.06301.x · Cited by 124
Self-citationFungal ATP-Binding Cassette (ABC) Transporters in Drug Resistance & Detoxification
Sipos, G., & Kuchler, K. (2006) · Current Drug Targets · doi:10.2174/138945006776359403 · Cited by 123
Self-citationCleary, J. D., Garcia-Effron, G., Chapman, S. W., & Perlin, D. S. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01568-07 · Cited by 118 · cited 1×
“CDR1, CDR2, SNQ2 Reduced azole resistance [25,26] FKS1, FKS2 Mutations lead to echinocandin resistance [27,28,29,30]”
BackgroundIdentifying infection-associated genes of Candida albicans in the postgenomic era
Wilson, D., Thewes, S., Zakikhany, K., Fradin, C., Albrecht, A., Almeida, R., Brunke, S., Grosse, K., Martin, R., Mayer, F., et al. (2009) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2009.00524.x · Cited by 115 · cited 1×
“albicans [5-10].”
Phenotypic switching and filamentation in Candida glabrata
Lachke, S. A., Joly, S., Daniels, K., & Soll, D. R. (2002) · Microbiology · doi:10.1099/00221287-148-9-2661 · Cited by 103
In-vivo selection of an azole-resistant petite mutant of Candida glabrata
BOUCHARA, J.-P., LE BOUDOUIL, S., FILMON, R., ZOUHAIR, R., HALLET, J.-N., CHABASSE, D., RENIER, G., & DEFONTAINE, A. (2000) · Journal of Medical Microbiology · doi:10.1099/0022-1317-49-11-977 · Cited by 88 · cited 1×
“glabrata [108-110].”
Kamran, M., Calcagno, A.-M., Findon, H., Bignell, E., Jones, M. D., Warn, P., Hopkins, P., Denning, D. W., Butler, G., Rogers, T., et al. (2004) · Eukaryotic Cell · doi:10.1128/ec.3.2.546-552.2004 · Cited by 75 · cited 5×
“glabrata Ace2 transcription factor of the RAM (Regulation of Ace2 transcription factor and polarized Morphogenesis) network [43], has been identified as a hypervirulence factor [17].”
BackgroundInfluentialPhenotypic Switching and Mating Type Switching of Candida glabrata at Sites ofColonization
Brockert, P. J., Lachke, S. A., Srikantha, T., Pujol, C., Galask, R., & Soll, D. R. (2003) · Infection and Immunity · doi:10.1128/iai.71.12.7109-7118.2003 · Cited by 75 · cited 1×
“prefer DB, whereas genetically identical cells from the oral cavity were predominantly displaying the Wh phenotype [68].”
BackgroundMacCallum, D. M., Findon, H., Kenny, C. C., Butler, G., Haynes, K., & Odds, F. C. (2006) · Infection and Immunity · doi:10.1128/iai.00817-06 · Cited by 45 · cited 4×
“In addition, the hypervirulent effect of ace2∆ cells is only observed in immunosuppressed mice [20].”
BackgroundInfluentialThierry, A., Bouchier, C., Dujon, B., & Richard, G.-F. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn594 · Cited by 45 · cited 4×
“For example, the BG2 strain contains 23, whereas the standard laboratory strain ATCC2001 (CBS138) strain carries only 17 EPA genes, lacking, for example, EPA4 and EPA5 [34,35].”
BackgroundInfluentialCandida glabrata tryptophan‐based pigment production via the Ehrlich pathway
Brunke, S., Seider, K., Almeida, R. S., Heyken, A., Fleck, C. B., Brock, M., Barz, D., Rupp, S., & Hube, B. (2010) · Molecular Microbiology · doi:10.1111/j.1365-2958.2010.07052.x · Cited by 37
Cited by
Candida Biofilms: Threats, Challenges, and Promising Strategies
Cavalheiro, M., & Teixeira, M. C. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00028 · Cited by 690
“Candida albicans is the most frequent pathogen responsible for Candida infections, followed by Candida glabrata (14).”
Backgroundde Oliveira Santos, G. C., Vasconcelos, C. C., Lopes, A. J. O., de Sousa Cartágenes, M. D. S., Filho, A. K. D. B., do Nascimento, F. R. F., Ramos, R. M., Pires, E. R. R. B., de Andrade, M. S., Rocha, F. M. G., et al. (2018) · Frontiers in Microbiology · doi:10.3389/fmicb.2018.01351 · Cited by 350
Candida Species Biofilms’ Antifungal Resistance
Silva, S., Rodrigues, C., Araújo, D., Rodrigues, M., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010008 · Cited by 302
Candida glabrata: A review of its features and resistance
Rodrigues, C. F., Silva, S., & Henriques, M. (2014) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-2009-3 · Cited by 268
Candida glabrata Biofilms: How Far Have We Come?
Rodrigues, C., Rodrigues, M., Silva, S., & Henriques, M. (2017) · Journal of Fungi · doi:10.3390/jof3010011 · Cited by 129
“glabrata infections is due to that same inherent low susceptibility to azoles [86] and that the acquired resistance is a result of rare mutations that are selected by drug pressure [87].”
Background
Metadata
- Authors
- Tscherner, M., Schwarzmüller, T., & Kuchler, K.
- Venue
- Pharmaceuticals
- Publisher
- MDPI AG
- Published
- 2011-01-11
- Volume
- 4
- Issue
- 1
- Pages
- 169-186
- ISSN
- 1424-8247 (ISSN-L)
- OpenAlex
- W2078938557
- Cited by
- 59
- References
- 59
- FWCI
- 2.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.